Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 19/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546033 | 0.84 | ERN1 (1.00) | ERN1 | |
| SCHEMBL3982574 | 0.83 | ERN1 (0.78) | ERN1 | |
| SCHEMBL5031416 | 0.82 | ERN1 (0.95) | ERN1 | |
| SCHEMBL1405241 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL29740541 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL29957335 | 0.78 | ERN1 (0.78) | ERN1 | |
| SCHEMBL14033478 | 0.78 | ERN1 (0.52) | ERN1 | |
| SCHEMBL12450080 | 0.78 | ERN1 (0.52) | ERN1 | |
| SCHEMBL2788053 | 0.78 | ERN1 (0.78) | ERN1 | |
| SCHEMBL29953689 | 0.78 | ERN1 (0.52) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2876108-B1 | COMPOUNDS OF CHIRAL AROMATIC SPIROKETAL DIPHOSPHINE LIGANDS, PREPARATION METHODS AND USES THEREOF | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2020-09-30 | — | — | EP | disclosed |
| CN-106604918-B | Polycyclic hERG activators | 诺华股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2018-05-10 | — | — | US | disclosed |
| CN-106604918-A | Polycyclic hERG activators | 诺华股份有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-9527862-B2 | Compounds of chiral aromatic spiroketal diphosphine ligands, preparation methods and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-12-27 | — | — | US | disclosed |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-20150252055-A1 | COMPOUNDS OF CHIRAL AROMATIC SPIROKETAL DIPHOSPHINE LIGANDS, PREPARATION METHODS AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-09-10 | — | — | US | disclosed |
| EP-2876108-A1 | COMPOUNDS OF CHIRAL AROMATIC SPIROKETAL DIPHOSPHINE LIGANDS, PREPARATION METHODS AND USES THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-8901134-B2 | Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901134-B2 | Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | ERN1 518/4885 |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | ERN1 518/4885 |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | ERN1 518/4885 |
| US-20150252055-A1 | COMPOUNDS OF CHIRAL AROMATIC SPIROKETAL DIPHOSPHINE LIGANDS, PREPARATION METHODS AND USES THEREOF | DDT, DPYD, RECQL | ERN1 691/4885 |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | ERN1 518/4885 |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | ERN1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.